Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trialCaicun Zhou, Jianjun Zou, Jifeng Feng et al.|The Lancet Respiratory Medicine|2020Cited by 504
P2.04-54 Characteristic of MSI-H Lung Cancer Patients Identified with Targeted Next-Generation SequencingXuefeng Xia, Yu Yi, Guofu Lin et al.|Journal of Thoracic Oncology|2019Cited by 4
1280P Sitravatinib + tislelizumab in patients with metastatic non-small cell lung cancer (NSCLC)Qing Zhou, Yi‐Long Wu, Xianjun Yu et al.|Annals of Oncology|2021Cited by 2